Search Results | MSF Science Portal

Journal Article

|

Pre-Print

Romo ML, LaHood A, Stagg HR, Mitnick CD, Trevisi L, et al.

2025-08-24 • medRxiv

People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...

Journal Article

|

Research

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W, et al.

2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article

|

Research

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, et al.

2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, et al.

2025-07-16 • Lancet Respiratory Medicine

Journal Article

|

Commentary

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C, et al.

2025-03-21 • Lancet Respiratory Medicine

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article

|

Research

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, et al.

2024-05-09 • Nature Communications

Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Research

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.

2024-01-25 • Clinical Infectious Diseases

BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...

Journal Article

|

Short Report

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, et al.

2024-01-25 • Clinical Infectious Diseases

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...

Journal Article

|

Research

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, et al.

2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article

|

Protocol

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.

2023-11-30 • Trials

BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Journal Article

|

Research

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ, et al.

2023-06-01 • American Journal of Respiratory and Critical Care Medicine

RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...

Journal Article

|

Research

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF, et al.

2023-06-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.

2023-04-28 • PLOS Global Public Health

Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...

Journal Article

|

Research

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.

2023-01-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

Journal Article

|

Commentary

McKenna L, Frick M, Angami K, Dubula V, Furin J, et al.

2023-01-01 • Nature Medicine

Journal Article

|

Commentary

Varaine FFV, Guglielmetti L, Mitnick CD

2017-07-17 • American Journal of Respiratory and Critical Care Medicine

Journal Article

|

Research

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, et al.

2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Journal Article

|

Review

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, et al.

2016-05-25 • PLOS One

INTRODUCTION
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...

Science Portal

Effect of smoking on drug-resistant tuberculosis treatment outcomes and exploring potential pathways: A multicountry cohort study

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Equitable, personalised medicine for tuberculosis: Treating patients, not diseases

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

The 1/4/6x24 campaign to cure tuberculosis quickly

Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Programmatic management of drug-resistant tuberculosis: an updated research agenda